Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer

Despite initial responses to targeted kinase inhibitors, lung cancer patients presenting with primary epidermal growth factor receptor (EGFR) mutations acquire resistance, often due to a second-site mutation (T790M). However, clinical trials found no survival benefits in patients treated with a mono...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Science signaling 2015-06, Vol.8 (379), p.ra53-ra53
Hauptverfasser:	Mancini, Maicol, Gaborit, Nadège, Lindzen, Moshit, Salame, Tomer Meir, Dall'Ora, Massimiliano, Sevilla-Sharon, Michal, Abdul-Hai, Ali, Downward, Julian, Yarden, Yosef
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Neoplasm - pharmacology Cell Line, Tumor Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics ErbB Receptors - metabolism Erlotinib Hydrochloride Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - metabolism Lung Neoplasms - pathology Mice Mice, Nude Receptor, ErbB-2 - antagonists & inhibitors Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism Receptor, ErbB-3 - antagonists & inhibitors Receptor, ErbB-3 - genetics Receptor, ErbB-3 - metabolism Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!